Maria Arquisola, MD
Psychiatry · Broken Arrow, OKNPI 1003846742
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,426 of the $5,037 with a category attached, or 87.9%. It is spread thinly across 23 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations.
Across 318 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$971
- Corium, LLC$819
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$646
- Teva Pharmaceuticals USA, Inc.$552
- Supernus Pharmaceuticals, Inc.$444
- Vanda Pharmaceuticals Inc.$319
- plus $1K from 17 others
What the payments were for
- Food & beverage$4,42688%
- Education$61112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 122 | $971 |
| Corium, LLC | 35 | $819 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $646 |
| Teva Pharmaceuticals USA, Inc. | 7 | $552 |
| Supernus Pharmaceuticals, Inc. | 13 | $444 |
| Vanda Pharmaceuticals Inc. | 19 | $319 |
| Lundbeck LLC | 16 | $254 |
| Ironshore Pharmaceuticals Inc. | 8 | $236 |
| Otsuka America Pharmaceutical, Inc. | 11 | $183 |
| Alkermes, Inc. | 8 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $90 |
| Tris Pharma Inc | 5 | $73 |
| Almatica Pharma LLC | 3 | $49 |
| Shire North American Group Inc | 3 | $43 |
| Sunovion Pharmaceuticals Inc. | 2 | $42 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Eisai Inc. | 2 | $28 |
| Merck | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Bausch Health US, LLC | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,037 in reported general payments places this provider in the 85th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 22 | $145,539 |
| Austedo XrDeutetrabenazine | 12 | $62,977 |
| RexultiBrexpiprazole | 27 | $49,488 |
| VraylarCariprazine Hcl | 31 | $42,682 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $29,900 |
| CaplytaLumateperone Tosylate | 14 | $22,334 |
| VyvanseLisdexamfetamine Dimesylate | 40 | $15,683 |
| Lurasidone Hcl | 36 | $11,959 |
| TrintellixVortioxetine Hydrobromide | 14 | $10,972 |
| XanaxAlprazolam | 12 | $7,559 |
| Duloxetine Hcl | 371 | $7,415 |
| Bupropion XlBupropion Hcl | 237 | $5,911 |
| Aripiprazole | 146 | $4,283 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 91 | $2,898 |
| Lisdexamfetamine Dimesylate | 14 | $2,891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $552 | $208,51634 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $183 | $49,48827 claims |
| AbbVieVraylar | $971 | $42,68231 claims |
| Alkermes, Inc.Lybalvi | $133 | $29,90017 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $90 | $26,65554 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $646 | $22,33414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Broken Arrow
- Robert MortonAda$1.9M
- Sarah LandTulsa$287K
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Marvin PeytonOklahoma City$60K
- Charles LesterMuskogee$39K
- Josephine DeguzmanOklahoma City$38K
- Jennifer MorrisEdmond$26K
- Julia IrwinNorman$16K
- Bradley McClureTulsa$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.